The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
15
06
2020
revised:
12
08
2020
accepted:
14
10
2020
pubmed:
23
10
2020
medline:
13
8
2021
entrez:
22
10
2020
Statut:
ppublish
Résumé
Glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase, has been implicated in the pathogenesis of many cancers, with involvement in cell-cycle regulation, apoptosis, and immune response. Small-molecule GSK-3β inhibitors are currently undergoing clinical investigation. Tumor sequencing has revealed genomic alterations in
Identifiants
pubmed: 33087512
pii: 1535-7163.MCT-20-0497
doi: 10.1158/1535-7163.MCT-20-0497
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
RNA, Messenger
0
Glycogen Synthase Kinase 3 beta
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-190Informations de copyright
©2020 American Association for Cancer Research.
Références
Domoto T, Pyko IV, Furuta T, Miyashita K, Uehara M, Shimasaki T, et al. Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 2016;107:1363–72.
Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, et al. Molecular pathways: revisiting glycogen synthase kinase-3β as a target for the treatment of cancer. Clin Cancer Res. 2017;23:1891–7.
Ugolkov A, Gaisina I, Zhang J-S, Billadeau DD, White K, Kozikowski A, et al. GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016;380:384–92.
Vincent EE, Elder DJE, O′Flaherty L, Pardo OE, Dzien P, Phillips L, et al. Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation. PLoS One. 2014;9:e114725.
Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 2006;12:5074–81.
Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005;334:1365–73.
Song EY, Palladinetti P, Klamer G, Ko K-H, Lindeman R, O’Brien TA, et al. Glycogen synthase kinase–3beta inhibitors suppress leukemia cell growth. Exp Hematol. 2010;38:908–21e1.
Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2011;71:835–45.
Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. Adv Biol Regul. 2017;65:5–15.
Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–31.
Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 2008;455:1205–9.
Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 2006;79:173–89.
Kroon J, in 't Veld LS, Buijs JT, Cheung H, van der Horst G, van der Pluijm G. Glycogen synthase kinase-3beta inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth. Oncotarget. 2014;5:8986–94.
Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol. 2010;31:24–31.
Beurel E. Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders. Neuroimmunomodulation. 2014;21:140–4.
Jellusova J, Cato MH, Apgar JR, Ramezani-Rad P, Leung CR, Chen C, et al. Gsk3 is a metabolic checkpoint regulator in B cells. Nat Immunol. 2017;18:303–12.
Li C-W, Lim S-Oe, Xia W, Lee H-H, Chan Li-C, Kuo C-W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.
Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 2018;78:6349–53.
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406:86–90.
Carneiro BA, Cavalcante L, Bastos BR, Powell SF, Ma WW, Sahebjam S, et al. Phase I study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3B) inhibitor, as a single agent and combined with chemotherapy in patients with refractory tumors. J Clin Oncol. 2020.
Ito H, Makiyama K, Kawahara T, Osaka K, Izumi K, Yokomizo Y, et al. The impact of gender difference on operative time in laparoscopic partial nephrectomy for T1 renal tumor and the utility of retroperitoneal fat thickness as a predictor of operative time. BMC Cancer. 2016;16:944.
Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, et al. Combination treatment with the GSK-3 inhibitor 9-ING-41 and CCNU cures orthotopic chemoresistant glioblastoma in patient-derived xenograft models. Transl Oncol. 2017;10:669–78.
Ding L, Liou GY, Schmitt DM, Storz P, Zhang JS, Billadeau DD. Glycogen synthase kinase-3beta ablation limits pancreatitis-induced acinar-to-ductal metaplasia. J Pathol. 2017;243:65–77.
Ding L, Madamsetty VS, Kiers S, Alekhina O, Ugolkov A, Dube J, et al. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1/ATR-mediated DNA damage response. Clin Cancer Res. 2019;25:6452–62.
Sahin I, Eturi A, De Souza A, Pamarthy S, Tavora F, Giles FJ, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biol Ther. 2019;20:1047–56.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–9.
Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812–4.
Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:1978–80.
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.
Patel P, Woodget JR. Glycogen synthase kinase 3: a kinase for all pathways?. Curr Top Dev Biol. 2017;123:277–302.
Lu S, Jiang Y, Lv J, Zou J, Wu T. Mechanism of kinase inactivation and nonbinding of FRATide to GSK3beta due to K85M mutation: molecular dynamics simulation and normal mode analysis. Biopolymers. 2011;95:669–81.
UniProtKB - P49841 (GSK3B_HUMAN). 2020.
Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina B, Knapp S, et al. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol. 2003;333:393–407.
Dajani R, Fraser E, Roe SM, et al. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 2003;22:494–501.
Pawloski JR, Randolph B, Bajio P. Foundation-one-heme next generation sequencing of hairy cell leukemia variant lymphocytes. Blood. 2016;128:5289.
Kim ST, Klempner SJ, Park SeH, Park JOh, Park YS, Lim HoY, et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget. 2017;8:77415–23.
Palomo V, Soteras I, Perez DI, Perez C, Gil C, Eugenia N, et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.. J Med Chem. 2011;54:8461–70.
Dembowy J, Adissu HA, Liu JC, Zacksenhaus E, Woodgett JR. Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis. Oncogene. 2015;34:3514–26.
Saegusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I. Crosstalk between NF-kappaB/p65 and beta-catenin/TCF4/p300 signalling pathways through alterations in GSK-3beta expression during trans-differentiation of endometrial carcinoma cells. J Pathol. 2007;213:35–45.
Yin Y, Kizer N, Thaker P, Chiappinelli K, Trinkaus K, Goodfellow P, et al. Glycogen synthase kinase 3beta inhibition as a therapeutic approach in the treatment of endometrial cancer. Int J Mol Sci. 2013;14:16617–37.
Ma C, Zeng C, Jin L, Yang Y, Li P, Chen L, et al. GSK3beta mediates the carcinogenic effect of HPV16 in cervical cancer. Sci Rep. 2015;5:16555.
Rath G, Jawanjal P, Salhan S, Nalliah M, Dhawan I. Clinical significance of inactivated glycogen synthase kinase 3beta in HPV-associated cervical cancer: relationship with Wnt/beta-catenin pathway activation. Am J Reprod Immunol. 2015;73:460–78.
Georgy SR, Cangkrama M, Srivastava S, Partridge D, Auden A, Dworkin S, et al. Identification of a novel proto-oncogenic network in head and neck squamous cell carcinoma. J Natl Cancer Inst. 2015;107:djv152.
Gao S, Li S, Duan X, Gu Z, Ma Z, Yuan X, et al. Inhibition of glycogen synthase kinase 3 beta (GSK3beta) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity. Mol Carcinog. 2017;56:2301–16.
Pramanik KK, Nagini S, Singh AK, Mishra P, Kashyap T, Nath N, et al. Glycogen synthase kinase-3beta mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion. Cell Oncol. 2018;41:47–60.
Zeng J, Liu D, Qiu Z, Huang Yi, Chen B, Wang L, et al. GSK3beta overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS One. 2014;9:e91231.
John JK, Paraiso KHT, Rebecca VW, Cantini LP, Abel EV, Pagano N, et al. GSK3beta inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol. 2012;132:2818–27.
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55.
Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K, et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019;10:4186.
Tavora F, Lotan T, Alves M, et al. Glycogen synthase kinase-3β expression in prostate cancer (PCa) correlates with aggressive pathological features and its blockade with 9-ING-41 inhibits viability of PCa cell lines [abstract]. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020Cancer Res 2020. 2020 Apr 27–28 and Jun 22–24;80.